Objectives To evaluate the health economics evidence based on randomized controlled trials of pharmacist-led medication review in pharmacotherapy managed cardiovascular disease risk factors, specifically, hypertension, type-2 diabetes mellitus and dyslipidaemia in ambulatory settings and to provide recommendations for future evaluations. Methods A systematic review was carried out according to the Cochrane Handbook for Systematic Reviews. PubMed (Medline), Scopus, Web of Science, National Health System Economic Evaluation Database (NHS EED), Cochrane Library, and Econlit were searched and screened by two independent authors. Incremental cost-effectiveness ratio was the main outcome. Risk of bias was assessed with the Effective Practice and Organisation of Care tool by the Cochrane Collaboration. Economic evaluation quality was assessed with the he Consensus Health Economic Criteria list (CHEC list). Results 5636 records were found, and 174 were retrieved for full-text review yielding 11 articles. Eight articles deemed the intervention as cost effective and two as dominant. Two cost-utility analyses were performed yielding ICERs of $612.7 and $59.8 per QALY. Four articles were considered to perform a high-quality economic evaluation and four had a low risk of bias. Future economic evaluations should consider cost-utility analysis, to describe usual care thoroughly, and use time horizons that capture the effect of cardiovascular disease prevention, a societal perspective and uncertainty analysis. Conclusion Pharmacist-led medication review has proven to be cost effective in various studies in different settings. Policy decision makers are advised to undertake local economic evaluations reflecting the gaps observed in this systematic review and published literature. If this is not possible, a transferability assessment should be conducted.
Introduction
Cardiovascular diseases (CVD) are a group of conditions encompassing coronary heart disease, cerebrovascular disease, and peripheral arterial disease [1] . The cost burden to healthcare systems of CVD includes direct and indirect costs [2, 3] . It is estimated that in the US alone, the cost of CVD accounts for more than $316 billion per year [2] and €210 billion per year in the European Union [3] . CVDs are caused by various factors including dyslipidaemia (DLP), hypertension (HTN), and type 2 diabetes mellitus (T2DM) which have been estimated to cost $34.8, $47.3, and $61.2 billion per year in the US [2] .
Current medications used to control CVD risk factors are safe, effective, and supported by evidence-based treatment guidelines [4] [5] [6] [7] . In spite of worldwide efforts led by the World Health Organisation to prevent the development of CVD through integrated strategies of multi-sector policies on risk factors, control of these diseases has proven to be elusive [1] . These outcomes might arise due to patients, prescribers, and system failures.
From a pharmaceutical perspective, there are several issues that could be contributing including drug-related problems, medication errors, and non-adherence. For example, a study showed in Sweden that preventing drug-related problems (an event involving drug therapy that actually or potentially interferes with desired health outcomes [8] ) could have potential cost savings of €358 million [9] . On the other hand, medication errors can be defined as "any preventable event that may cause or lead to inappropriate medication use or patient harm" [10] , are a key component of drug-related problems, and can have costs that could be as high as €111,727.1 [11] .
One intervention to address medication-related issues is medication reviews (MRs). These are defined as "a structured evaluation of a patient's medicines with the aim of optimising medicines use and improving health outcomes. This entails detecting drug-related problems and recommending interventions" [12] . There are three types of MRs which are classified according to the patients´ information available to the reviewer and hence the depth of the review. Simple or type 1 MR aims to identify drug interactions, some side effects, and some adherence problems and is based only on the medication history available in the pharmacy. Type 2 or intermediate MR uses patient interview or general medical practitioners (GPs) information in addition to the medication history. This review can detect some effectiveness and safety problems. Finally, Type 3 or advanced MR is the most comprehensive review that can detect most of medication-related issues and utilizes all previously cited sources of information [13] . Pharmacists have been performing MRs in various settings, showing promising results. In an overview of systematic reviews of community pharmacists, meta-analyses suggest positive impact on glycosylated haemoglobin (HbA1c), blood pressure, cholesterol, number and appropriateness of medications [14] . Positive results have also been observed in general practices, where pharmacists and GPs work together on the same health centre, showing benefits on systolic and diastolic blood pressure (SBP and DBP, respectively), HbA1c, cholesterol, and cardiovascular risk [15] .
Professional pharmacy services targeting CVD risk factors management have also shown positive economic outcomes in systematic reviews [16] [17] [18] . A review targeting secondary prevention of CVD and heart failure reported clinical and economic outcomes of clinical pharmacist interventions for hospitalized patients and outpatients. All but one of the eight economic studies reported favourable results.
However, not all studies were full economic evaluations (EE) [16] . Another study assessed team-based care, an intervention that includes interdisciplinary work of GPs, pharmacists, nurses, and other providers. They found a median incremental cost-effectiveness ratio (ICER) of $13,992 per quality-adjusted life years (QALY) [18] . For T2DM, a systematic review evaluated studies of pharmacist-led services (education, pharmacotherapeutic monitoring, health screening, immunization, and pharmacokinetics) and found a range of cost savings ranging from $8 to $85,000 2014 US dollars [17] . However, none of these systematic reviews addressed specifically full EE based on Randomized Controlled Trials (RCT) which are better suited to aid decision makers to adopt these services and, on the other hand, included various services provided by pharmacists [19] . Taking into account that positive clinical outcomes have been found for MR on CVD risk factor control, if this intervention proves to be cost effective, it might yield the possibility to avert costs or maximize the utility, where resources are scarce.
Therefore, the aim of this systematic review is to evaluate the health economic evidence based on RCTs of pharmacistled MR in pharmacotherapy managed cardiovascular disease risk factors, specifically, HTN, T2DM, and DLP in ambulatory settings and to provide recommendations for future EEs.
Methods
The Cochrane Handbook for Systematic Reviews was followed [20] . For reporting purposes, the PRISMA statement was used [21] . The study protocol is published in PROS-PERO (ID CRD42018085943).
Article retrieval and screening
The following databases were searched from inception to October 2018: PubMed (Medline), Scopus, Web of Science, National Health System Economic Evaluation Database (NHS EED), Cochrane Library, and Econlit. An example of the search strategy for PubMed is shown in Appendix 1 in Supplementary material. In addition, personal records were searched.
Screening of papers was undertaken by title and abstract review. This was done by two authors (AA and FM). The process was over inclusive, so only obviously irrelevant reports were removed. Any discrepancies were discussed to reach agreement. If this was not possible, a third researcher (VGC) was contacted. Included articles were retrieved and multiple reports of the same study were linked. Full-text papers were read and studies were selected according to the inclusion/exclusion criteria.
Data extraction, quality assessment, and analyses
A data extraction sheet was developed and piloted for data retrieval (Appendix 2 in Supplementary material). The main study outcome was ICER. If it was not stated in the original paper and data for calculation was available, it was computed when effects had a statistically significant difference [22] . For risk of bias assessment of RCTs on which the EEs were based, the Effective Practice and Organisation of Care (EPOC) tool was used [23] . Other risks of bias considered were blinding of data analysis. It was considered as high risk if researchers were also pharmacists. Studies were deemed as low risk of bias when they had at least six domains as low risk. Conversely, they were classified as high risk when five or more domains had high risk [24] . For quality assessment of EEs, the Consensus Health Economic Criteria list (CHEC list) was used [25] . If the evaluation was model-based, the Phillips checklist was applied [26] . The EEs were classified as high quality if they scored above 75%, medium quality between 51 and 74%, and low quality if scored below 50% [24] . Overall EE quality was categorized as high (+++), medium (++), or low (+) [24] . To categorize a study as high overall quality (+++), it had to be a high-quality EE and the RCT had to have a low risk of bias. Low overall EE quality (+) was stated if the EE quality was low or if the RCT had a high risk of bias. Medium quality was assigned (++) if the EE was considered as medium quality and it had medium or low risk of bias, or if it had medium risk of bias and high quality.
To compare results between countries, incremental costs and ICERs were transformed to a common year and currency (USD and 2016 prices) through the online tool developed by Cochrane Economics Methods Group and the Evidence of Policy and Practice Information and Coordinating Centre. This tool uses Purchasing Power Parities (PPP) to adjust estimates for costs and price year [27] . PPP values of the International Monetary Fund were used.
Results are presented in a summary table and in text. They were also synthesized through the permutation matrix [28] . This matrix has nine different possibilities classifying the interventions in terms of incremental costs (less costly, equal costs, or more expensive than the alternative) and incremental effectiveness (less effective, equal effectiveness, or more effective than the control intervention). Meta-analysis was not considered, because different resource uses and costs differ widely among countries or local settings [20] .
Results

Study selection
5636 records were identified in the search, and after removal of duplicates, 4592 records were screened by title and abstract. Of them, 174 were retrieved for full-text review yielding 11 articles for data extraction and analysis, as described in Fig. 1 . Most of the studies were excluded, because they were not based on an RCT or C-RCT.
Characteristics of included studies
Of the included studies, five were carried out in the US [29] [30] [31] [32] [33] . The remaining six were from Brazil [34] , Canada [35] , China [36] , Nigeria [37] , Taiwan [38] , and the UK [39] . Two studies were implemented in community pharmacies [32, 39] and the rest in primary care centres [29, 30, [33] [34] [35] or hospital-based outpatient clinics [31, [36] [37] [38] . All the studies included follow-up of patients and all but one had at least one face-to-face interview [33] . Besides MR, two trials described comprehensive adherence interventions with other resources besides counselling. One of the trials gave pharmacists a standardised questionnaire to assess barriers to medication adherence with an algorithm to overcome them and provided patients a take-home toolkit that included a wallet card for recording blood pressure readings, a pillbox for 7 days, leaflets, and a pedometer [32] . The other trial by Chan et al. described an intervention that addressed adherence, knowledge and benefits, skills, perceived health, and cognitive functions [36] . Almost all the studies assessed type 3 MR, meaning that they undertook a comprehensive analysis, interviewing the patient and having access to their medication history and clinical records. There was one exception, where they did not had access to GP notes [32] . As for the methods of collaboration with GPs, in three trials, pharmacist provided a written report [32, 36, 39] . Other ways of communication were through electronic medical record [33] , face-to-face meetings [30] , and by telephone [31] . Seven trials reported the training of the pharmacists and differed widely from a certified diabetes educator to online training courses [30, 32-35, 38, 39] .
In most of the trials, cost effectiveness of the interventions was described [29-33, 35, 36, 38, 39] . Two other studies developed a cost-utility analysis [34, 37] . Eight used the third payer perspective [31] [32] [33] [34] [35] [37] [38] [39] , two adopted a societal point of view [29, 30] and one from a single provider standpoint [36] . Three studies did not state the perspective explicitly [29, 36, 39] . Eight studies quantified costs of medications [29-32, 34, 35, 37, 38] , six of GPs time [30-32, 34, 37, 39] , six hospitalizations [29, 32, 35, [37] [38] [39] , and four emergency visits [29, 32, 34, 37] . Other costs evaluated were training of pharmacists [33, 39] , materials for adherence interventions [32, 33, 37, 38] , laboratory tests [37] , and fixed costs [33] . Outcomes were presented in five studies as SBP [29] [30] [31] [32] [33] , DBP [29] [30] [31] [32] [33] , and HTN control [30] [31] [32] [33] 39] , three as quality of life [34, 37, 39] , and two for CVD risk [35, 36] . Other outcomes reported were life years gained [33] , refill adherence [32] , and HbA1c [38] . In general, time horizons were no longer than 12 months, except for a study that lasted 36 months [34] . None of the included studies considered modelling. In addition, none declared competing interests with most receiving grants from governmental offices. One had financing from a pharmaceutical company [31] and another from a university [36] . A summary of trials characteristics can be found in Table 1 .
Main findings
Findings are summarized in Table 2 and are represented graphically in Fig. 2 . CVD risk was evaluated in two studies using different formulas. A study evaluated 5 year risk with an equation adapted for Chinese populations [36] , whilst another used an annualized version of the United Kingdom Prospective Diabetes Study (UKPDS) [35] , making them difficult to compare. The incremental effects of SBP and DBP varied from 11.0 [31] to 5.6 [32] mmHg and from 4.1 [33] to 1.0 [31] mmHg, respectively. HTN control ranged from 25 [33] to 9% [30] . Finally, when incremental QALYs were calculated, they ranged from 0.12 [37] to 1.32 [34] . On the other hand, incremental costs were less for the intervention Fig. 1 Systematic review flowchart of study selection. NHS EED National health system economic evaluation database, RCT randomized controlled trial, MR medication review, EE economic evaluation, CVD cardiovascular diseases when compared to the control group in two studies [31, 35] . For trials, where costs were higher than usual care, they reported up to $432.1 per patient in 2016 US dollars [33] . As for ICERs, one had to be recalculated, because the original estimation did not consider incremental effects, failing to discount the control arm [38] . In another EE, ICERs had to be calculated, because they had not calculated directly usual care against MR [33] . For cost-effectiveness studies evaluating HTN, one trial was dominant over usual care in SBP, DBP, and HTN control [31] . For SBP, ICERs ranged from $48.6 [33] to $25.3 per mm/Hg [32] . For DBP, they ranged from $105.4 [33] to $3.5 per mm/Hg [29] . When HTN control was assessed, a study evaluated the ICER to reach patient control and valuated it at $757.6 per patient [32] . Another study assessed the cost per % of patients achieving BP and had a result of $23.4 [30] per 1% of patients reaching their BP goal. Finally, the two cost-utility studies had values of $612.67 [37] and $59.8 [34] per QALY.
Uncertainty analysis was carried out in four studies yielding positive results [32, 33, 35, 37] . Three used bootstrap [32, 33, 35] and one Monte Carlo simulation [37] . Two of them presented their results in the cost-effectiveness plane [35, 37] . One study yielded 99% of the simulated ICERs as cost effective and 66% of them as dominant [35] . The other trial considered 93.8% of the iterations as cost effective and 5.6% of them as dominant [37] . These studies built acceptability curves yielding willingness to pay for a probability of 95% of them being cost effective of $3303 per 1% reduction in annualized CVD risk [35] and $3607 per QALY gained [37] .
Most of the evaluated studies deemed MR as more effective than usual care, but also more expensive [29, 30, [32] [33] [34] [36] [37] [38] . Two interventions dominated usual care, meaning that usual care caused more costs and was less effective [31, 35] . Conversely, a study did not find any difference between incremental effects and was valued as more expensive; [39] No significant effects $257.79 per patient Intervention was dominated therefore, its adoption was not recommended in that setting (dominated) [39] .
Risk of bias and quality assessment
Of the 11 EEs, four reported the clinical trial in a separate publication [40] [41] [42] [43] . No study could blind their patients to the intervention, but given the nature of MR, it was not considered as a risk of bias. On the other hand, two studies declared blinding of outcome assessment [33, 39] , and also two were free of contamination between groups, as they were randomized by centre [30, 32] . Regarding the quality of the EEs, low scores in appropriate time horizon, insufficient description of control group, lack of adequate perspective, and uncertainty treatment were observed. As for time horizon, all but one [34] of the studies lasted between 6 and 12 months. A societal perspective was used in two studies [29, 30] . In the case of the competing alternatives, three studies described with some detail usual care in addition to regular consultation with GPs [34, 37, 38] . Finally, uncertainty treatment was used in four trials [32, 33, 35, 37] . Overall quality of the studies is described in Table 3 , with two of the them achieving high quality in EE assessment with a low risk of bias [33, 35] . For more details of risk of bias in each domain or EE quality, see Appendices 3 and 4 in Supplementary material.
Discussion
In this systematic review, full EEs of pharmacist-led MR on outpatients with CVD risk factors are described and assessed. Most of the EEs deemed MR as cost effective, but transferability assessment or evaluation in local setting is encouraged to assess the implementation of this professional pharmacy service in the context of current clinical guidelines, pharmacist training, and the health-care system. In regards of other similar studies, they have shown positive economic impact, but have analysed partial economic evaluations, other groups of patients, and other services [16] [17] [18] . The systematic review from Altowaijri et al. included studies that either used MR or educational interventions for CVD risk factor in patients with coronary heart disease and heart failure in any setting [16] . Most of the economic studies included were in community pharmacy. Of these, three studies assessed smoking services, two T2DM, and one each for coronary heart disease, DLP and HTN. The only cost-utility study was carried out for a smoking aid service. The only study, where MR was dominated, was the MEDMAN study and will be discussed later [39] . Wang et al. included studies that intervened through an array of interventions in patients with T2DM [17] . They found 25 EE studies, where 21 carried out MR, 11 were full EE, and of them, six were cost-benefit analysis, five cost effectiveness, and one cost-utility. All had positive results with the cost-utility analysis that yielded the intervention as dominant. Most of the individual studies cited in these reviews were not included in this paper, because they were not based on RCTs (three of them met our inclusion criteria [29, 31, 39] ). Finally, this is the most recent systematic review on this topic, including many recent studies not included in the previous reviews.
Cost-effectiveness analysis
Most of the studies in this review evaluated the intervention as cost effective and two classified it as dominant [31, 35] . It is important to highlight that most of the ICERs are below $100, but this should be interpreted with caution, as these are secondary outcomes, e.g., 1 mm/Hg per dollar. When outcomes such as coronary heart disease event avoided are analysed, the ICER could be as high as $4352 [36] . As for cost-utility results, the two studies reporting QALYs for MR had ICERs that did not surpass $612 [34, 37] . Furthermore, one of these studies [37] compared the ICER to standards of the Cost-effectiveness Threshold (CET) of $50,000, £30,000 or 1-3 Gross Domestic Product (GDP) per-capita, even though these values may be considered as too high, leading to the incorrect approval of interventions [44] . Adoption of services that are not cost effective is critically important in low-and middle-income countries, where budget constraints are an issue. Some authors suggest using a "supply-side" CET of about 0.6 GDP per-capita, although even using that CET, for both countries (Brazil and Nigeria), the intervention could be considered as cost effective [45] .
An important issue is type of resources recorded. EE reported pharmacist training [33, 39] , emergency visits [29, 32, 34, 37] , and hospitalizations [29, 32, 35, [37] [38] [39] . Furthermore, no study evaluated indirect costs such as loss of productivity. Two EE declared to have a societal perspective, but the only cost borne by patients was medications due to their own country's health system [29, 30] .
Transferability
Although 10 of the 11 studies reported MR as cost effective, these results should be considered carefully, as heterogeneity between trials and health-care systems may limit recommendation for their adoption in other countries or settings without carrying out a transferability analysis. For example, some of the trials differed on the components of the intervention, as some of them used various adherence aids [32, 36] . In one study, where the intervention was deemed as cost effective, pharmacists intervened face-to-face with GPs, a fact that could be considered an advantage as the relationship and inter-professional collaboration could reach a higher level than communication through written reports [30] . Nevertheless, another trial showed that through an electronic communication system with GPs and telephone interviews with patients, positive results could also be achieved [33] . On the other hand, one study in community pharmacies addressed the issue of not accessing clinical records by providing pharmacists some basic clinical information. This study failed to achieve positive outcomes [39] . Most of the studies used type 3 MR, i.e., undertaking a patient interview, having access to medication records and patients´ clinical history. This blurs the conclusion that the effects observed are due to the interaction with GPs or patients. All studies included patient follow-up which has been recently reported by a systematic review to be a determinant of MR effectiveness. Interestingly, when pharmacists had only one encounter with patients, no effect was found [36] Medium Medium Medium Obreli-Neto et al. 2015 [34] Medium Medium Medium on mortality, hospitalizations, falls, physical, and cognitive functioning [46] . Another important issue is the definition of usual care, as it may be different across countries, health systems, and even health-care providers. For example, one of the included studies compared pharmacist-led MR plus a home blood pressure monitor with two alternatives. One was usual care that included pamphlets, a wallet with a registry of their blood pressure and a web site that allows to schedule appointments, refill prescriptions, view medical records, lab results, and to communicate with their provider. The other alternative included usual care plus a home blood pressure monitor [33] . The type of inclusion and exclusion criteria might also affect transferability. For example, Okamoto et al. included only patients taking specific medications [29] . If a decision maker would like to use these results, they should assess if those medications are recommended on their guidelines. For example, in this case, they used nifedipine, verapamil, captopril, diltiazem, clonidine, terazosin, propranolol, or lisinopril that at the time of the study were more costly, so more economic impact was expected, but currently, they are not recommended as first line treatment for HTN [47] . Pharmacist training was described in seven studies and differed on the competencies and contents [30, 32-35, 38, 39] . Different studies estimated how many resources were used which may alter the results. A trial that estimated pharmacy technicians' time could affect the ICER if it is a main cost driver [32] .
Risk of bias
Four of the EEs were classified as high quality, and of these, two had a medium risk of bias in the clinical trial potentially affecting final conclusions [37, 38] . It should be noted that we did not consider blinding of the patients that received MR a bias due to the nature of the intervention. Some of the most frequent sources were lack of blinding of outcome assessment with only two studies undertaking the blinding [33, 39] . This is a key issue, since most of the investigators were pharmacists. Two of the eleven studies considered a cluster-RCT design which minimises the risk of contamination between groups [30, 32] .
Economic evaluation quality assessment
When EE alongside clinical trials of CVD are analysed it is worth noting these diseases develop over several years, so modelling should be considered to predict longer time horizons, ideally of a lifetime. CVD risk is summed as a probability of over 5-10 years, but events can happen at any time through a lifetime [36] . For example, a study developed a Markov model cohort simulation through lifetime to predict acute coronary syndrome, stroke and heart failure using the conservative assumption that the intervention would stop at 6 months and its effect would go back to baseline in 2 years. They built a cohort based on other trials and found that 48.6% of the iterations, MR would be cost effective with a CET of $50.000 [48] . On the other hand, if time horizons are longer than 1 year, discount rate should be applied for costs and effects depending on local guidelines or international standards, so time preference could be adjusted to the present values. The only study in this systematic review carried out for more than 1 year did not to take this into account [34] . Three studies described usual care as GP consultation which makes comparison complex, as every country or even health centre has different clinical protocols that may change resource utilization and baseline outcomes [34, 37, 38] . Furthermore, two other studies described a control group with other interventions such as guidelines for lowering blood pressure, pamphlets, or websites that might mean a higher baseline compared to the studies that only used GP consultation [32, 33] .
Finally, as costs and effects are evaluated in a sample, population values may vary. In this context, uncertainty analysis is always recommended to assure that the results represent opportunity costs of other interventions forgone. Only four studies made this analysis [32, 33, 35, 37] , but two of them took a step further building presentation devices for decision making as a cost-effectiveness planes and acceptability curves with 99% and 93.8% of the simulated ICERs as cost effective and willingness to pay $3303 per 1% reduction in annualized CVD risk and $3607 per QALY gained [35, 37] .
Limitations
This systematic review is not free of publication bias, as there could be trials with negative outcomes that have not been published intentionally in peer reviewed journals, or as it is generally accepted, negative results are less likely to be published. In our review, the grey literature was not searched, but related personal records were included. However, we searched six different databases and platforms from health and economic background in an attempt to address this issue. We do acknowledge that model-based studies are recommended to project outcomes for longer periods of time; however, these were excluded from our review, as data were not based on RCTs. Decision-makers´ requirements are a key issue, as they define the decision problem and might yield some alternatives in the studies as irrelevant to their specific jurisdiction. In addition, as national guidelines differ, specific methodological quality might be required to be used in local settings. These guidelines might establish particular time horizons, perspectives, discount rates, and unit costs which may need to be taken into account [49] .
Recommendations
As a product of this systematic review, an evidence-based set of recommendations are made for pharmacist-led MR on CVD risk factors EE conducted alongside clinical trials:
-Type of economic evaluation Cost-utility analysis is encouraged, so patients' preferences, who are the final recipients of health technologies, are represented. This approach allows comparison of MR with other interventions to represent opportunity costs for society. -Comparator Usual care or any other comparator must be described thoroughly, as countries' health-care systems or even health centre procedures vary. -Time horizon Because of the nature of CVD, effects (clinical outcomes or quantity and quality of life) and costs of MR on HTN, T2DM, and DLP can impact through the life span of patients. Longer time horizons should be explored. If necessary, modelling should be tried. -Perspective Societal perspective should be used, as indirect costs might account as an important source of resources used. From this perspective, other narrower ones can be derived if the decision maker requires it. In addition, it should be explicitly stated on the methods. -Resources All relevant resource consumption should be evaluated. This include direct costs such as pharmacists', other professionals' or technicians' time, drug costs, the intervention itself, emergency room visits, hospitalizations, training, laboratory tests, and indirect costs such as productivity loss, patient transportation, and carers among others. -Uncertainty analysis To represent as accurately as possible opportunity costs for the target population, an uncertainty analysis needs to be undertaken to assure that information delivered to the decision makers' added value to the selection of health interventions.
Conclusions
Most of the EE considered the intervention to be cost effective with four being rated of high quality. This analysis provides encouragement to decision makers to perform local evaluations, so local clinical pathways, resource use, and professional expertise can be measured. We recommend the use of cost-utility analysis, thorough description of the comparator (usual care), time horizons that can capture the effect of CVD prevention, use of a societal perspective, and use of uncertainty analyses. If this is not possible, a transferability assessment should be performed, so decision makers can use this information in their jurisdiction.
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